Baxter (NYSE:BAX) and Miromatrix Medical (Nasdaq:MIRO) today announced a collaborative research agreement on acute liver failure (ALF) treatments.
As part of the collaboration, Eden Prairie, Minnesota-based Miromatrix created a new liver therapy. The therapy, called MiroLiverELAP, combines a Miromatrix single-use bioengineered liver with Baxter’s PrisMax system.
Miromatrix designed the MiroLiverELAP to provide external support to the patient’s native liver. As a bridge-to-transplant or bridge-to-recover option, it potentially helps to avoid a liver transplant.
Baxter is both a collaborator and shareholder of Miromatrix.
Miromatrix submitted an investigational new drug (IND) application for the therapy to the FDA in November 2022. The company said in a news release that it “appears to be” the first IND for a bioengineered organ. It also plans to commence a Phase 1 clinical trial using MiroLiverELAP to treat patients sufferin…